Back to Search
Start Over
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
- Source :
-
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2018 Apr; Vol. 103 (4), pp. 574-581. Date of Electronic Publication: 2018 Feb 02. - Publication Year :
- 2018
-
Abstract
- The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.<br /> (© 2018 American Society for Clinical Pharmacology and Therapeutics.)
- Subjects :
- Anticonvulsants pharmacology
Humans
Pharmacogenetics methods
Pharmacogenetics standards
Carbamazepine pharmacology
Drug-Related Side Effects and Adverse Reactions genetics
Drug-Related Side Effects and Adverse Reactions prevention & control
HLA-B Antigens genetics
Oxcarbazepine pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1532-6535
- Volume :
- 103
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinical pharmacology and therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 29392710
- Full Text :
- https://doi.org/10.1002/cpt.1004